CINECA IRIS Institutional Research Information System

Background Many clinical and epidemiological studies have measured the prevalence of IgE sensitization using skin tests and/or serum-specific IgE. Most of them have been done in only one country using a battery of selected allergens relevant to that country. In multi-centre studies, the number of tested allergens is often limited by the cost. It is therefore difficult to compare prevalence of sensitized subjects between studies. Objective To define the number and the type of allergen that should be tested in order to characterize a person as sensitized. Method Subjects were selected from the European Community Respiratory Health Survey I. All subjects underwent skin prick tests to nine of the most common allergens. In addition, two local allergens were tested in some centres. Result Using nine allergens, 35.6% of the 11 355 subjects were sensitized. The prevalence of sensitization increased with the number of tested allergens. Seven allergens enabled the identification of almost all sensitized subjects, adding another one inducing, in most countries, an increase of prevalence under 0.5%. Adding one local allergen to the battery of tests increased the overall estimated prevalence by only 1%. This increase was not seen in Ireland and was less marked in the United Kingdom (0.3%) but was greater in France (2.6%), Australia (2.5%) and Belgium (1.9%). Conclusion Seven selected allergens (Dermatophagoides pteronyssinus, cat, grass, birch, olive pollen, Alternaria and Cladosporium) allow the identification of almost all sensitized subjects in epidemiologic studies. Inclusion of local allergen should be considered in a standard panel for international studies.

Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I

BUCCA, Caterina;ROMANO, Canzio;
2007-01-01

Abstract

Background Many clinical and epidemiological studies have measured the prevalence of IgE sensitization using skin tests and/or serum-specific IgE. Most of them have been done in only one country using a battery of selected allergens relevant to that country. In multi-centre studies, the number of tested allergens is often limited by the cost. It is therefore difficult to compare prevalence of sensitized subjects between studies. Objective To define the number and the type of allergen that should be tested in order to characterize a person as sensitized. Method Subjects were selected from the European Community Respiratory Health Survey I. All subjects underwent skin prick tests to nine of the most common allergens. In addition, two local allergens were tested in some centres. Result Using nine allergens, 35.6% of the 11 355 subjects were sensitized. The prevalence of sensitization increased with the number of tested allergens. Seven allergens enabled the identification of almost all sensitized subjects, adding another one inducing, in most countries, an increase of prevalence under 0.5%. Adding one local allergen to the battery of tests increased the overall estimated prevalence by only 1%. This increase was not seen in Ireland and was less marked in the United Kingdom (0.3%) but was greater in France (2.6%), Australia (2.5%) and Belgium (1.9%). Conclusion Seven selected allergens (Dermatophagoides pteronyssinus, cat, grass, birch, olive pollen, Alternaria and Cladosporium) allow the identification of almost all sensitized subjects in epidemiologic studies. Inclusion of local allergen should be considered in a standard panel for international studies.
2007
37
780
787
ALLERGIC SENSITIZATION EPIDEMIOLOGY
Bousquet P-J, Hooper R, Kogevinas M, Jarvis D and Burney P. Participating Centres: Australia: Michael Abramson, MB, BS, PhD, Jozica Kutin, BA, MPsych, (Melbourne); Belgium: Paul Vermeire, MD, Frank van Bastelaer, MD, (Antwerp South, Antwerp Central); France: Jean Bousquet, MD, (Montpellier); Francoise Neukirch, MD, Renata Liard, PhD, (Paris); Isabelle Pin, MD, Christophe Pison, MD, (Grenoble); Andre Taytard, MD, (Bordeaux); Germany: Helgo Magnussen, MD, Dennis Nowak, MD, (Hamburg); H-Erich Wichmann, MD, Joachim Heinrich, MD (Erfurt); Iceland :Thorarinn Gislason, MD, PhD, H. David Gislason, MD, (Reykjavik); Ireland: the late John Prichard, D Phil, FRCPI, Shane Allwright, PhD, Dominic MacLeod, MB, BSc, (Dublin); Italy: Massimiliano Bugiani, MD, Caterina Bucca, MD, Canzio Romano, MD, (Turin); Roberto de Marco, MD, Vincenzo Lo Cascio, MD, Cesare Campello, MD, (Verona); Alessandra Marinoni, MD, Isa Cerveri, MD, Lucio Casali, MD, (Pavia); Netherlands: Bert Rijcken, MD, PhD, Anja M. Kremer, MD, PhD, (Groningen, Bergen-op-Zoom, Geleen); New Zealand: Julian Crane, FRACP, Simon Lewis, BSc, (Wellington, Christchurch, Hawkes Bay); Norway: Around Gulsvik, MD, PhD, Ernst Omenaas, MD, PhD, (Bergen); Spain: Josep M. Anto, MD, Jordi Sunyer, MD, Felip Burgos, Resp Tech, Jordi Castellsague, MD, Josep Roca, MD, Joan Soriano, MD, Aureli Tobias, BSc, Dip Stat,(Barcelona); Nerea Muniozguren, MD, Jacinto Ramos-Gonzalez, MD, Alberto Capelastegui, MD, (Galdakao); Jose Castillo, MD, Jose Rodriguez-Portal, MD,(Seville); Jesus Martinez-Moratalla, MD, Enrique Almar-Marqnes, MD, (Albacete); Jose Maldonado-P´erez, MD, Antonio Pereira, MD, Jose Sfinchez-Ramos, MD (Huelva); Roman Quiros, MD, Ismael Huerta, MD, Felix Payo-Losa, MD (Oviedo); Sweden: Gunnar Boman, MD, PhD, Christer Janson, MD, PhD, Eythor Bj ¨ornsson, MD, PbD, (Uppsala); Leif Rosenhall, MD, PhD, Eva Norrman, MD, Bo Lundbgck, MD, PhD (Umefi), Nalle Lindholm, MD, PhD, Peter Plaschke, MD (Goteborg); Switzerland: Ursula Ackermann-Liebrich, MD, Nino Kunzli, MD, Andre Perruchoud, MD (Basel);United Kingdom: Michael Burr, MD, Jane Layzell, MRCGP, (Caerphilly); B. Russell Hall, MD, (Ipswich); Brian Harrison, FRCP, (Norwich); John Stark, MD, (Cambridge); United States: A. Sonia Buist, MD, William M. Vollmer,PhD, Molly L. Osborne, MD, PhD, (Portland).
03A-Articolo su Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/126015
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 58
social impact